Company: M’s Science Corporation
Drug Type: Small Molecule
Conditions: ALS, depression, stroke
Mechanism Type: Sigma-1 receptor (S1R) agonist
Mechanism: Cutamesine is a highly selective sigma-1 receptor (S1R) agonist, which is being developed for ALS. S1R mutations are associated with juvenile ALS, and mouse studies suggest S1R agonists may have therapeutic benefit in ALS.
U.S. Status for ALS: N/A
 Pipeline. M’s Science Corporation, 2015. Accessed 9 March, 2016 from http://www.m-sci.com/e/pipeline/cutamesine.html
 A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Al-Saif, A et al. Ann Neurol. 2011 Dec;70(6):913-9.
 Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS). Mavlyutov, TA et al. J Pharmacol Sci. 2015 Jan; 127(1): 10–16.
 Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Urfer, R et al. Stroke. 2014 Nov;45(11):3304-10.
Last updated March 9th, 2016